Anti-CYP1B1 antibody [EPR14972] - C-terminal
- RabMAb
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(27 Publications)
Rabbit Recombinant Monoclonal CYP1B1 antibody. C-terminal. Suitable for WB, IHC-P and reacts with Rat, Human samples. Cited in 27 publications.
View Alternative Names
Cytochrome P450 1B1, CYPIB1, Hydroperoxy icosatetraenoate dehydratase, CYP1B1
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CYP1B1 antibody [EPR14972] - C-terminal (AB185954)
Immunohistochemical analysis of paraffin-embedded Human renal adenocarcinoma tissue labeling CYP1B1 with ab185954 at 1/500 dilution followed by pre-diluted HRP-conjugated secondary antibody and counter-stained with Hematoxylin.
Perform heat mediated antigen retrieval with EDTA buffer pH 9 before commencing with IHC staining protocol.
- WB
Lab
Western blot - Anti-CYP1B1 antibody [EPR14972] - C-terminal (AB185954)
Western blot : Anti-CYP1B1 antibody [EPR14972] (ab185954) staining at 1/5000 dilution, shown in black; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab185954 was shown to bind specifically to CYP1B1. A band was observed at 55 kDa in wild-type A549 cell lysates with no signal observed at this size in CYP1B1 knockout cell line ab269476 (knockout cell lysate ab269641). To generate this image, wild-type and CYP1B1 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times before development with a high-sensitivity ECL substrate kit and imaged with 8 minutes exposure time. Secondary antibodies used were HRP conjugated Goat anti-Rabbit (H+L) and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
All lanes:
Western blot - Anti-CYP1B1 antibody [EPR14972] - C-terminal (ab185954) at 1/5000 dilution
Lane 1:
Wild-type A549 cell lysate at 20 µg
Lane 2:
CYP1B1 knockout A549 cell lysate at 20 µg
Lane 2:
Western blot - Human CYP1B1 knockout A549 cell lysate (<a href='/en-us/products/cell-lysates/human-cyp1b1-knockout-a549-cell-lysate-ab269641'>ab269641</a>)
Lane 2:
Western blot - Human CYP1B1 knockout A549 cell line (<a href='/en-us/products/cell-lines/human-cyp1b1-knockout-a549-cell-line-ab269476'>ab269476</a>)
Lane 3:
HeLa cell lysate at 20 µg
Lane 4:
MCF7 cell lysate at 20 µg
Lane 5:
SiHa cell lysate at 20 µg
Lane 6:
Human Brain cell lysate at 20 µg
Lane 7:
Human Kidney cell lysate at 20 µg
Lane 8:
Human Liver cell lysate at 20 µg
Lane 9:
HepG2 cell lysate at 20 µg
Lane 10:
LoVo cell lysate at 20 µg
Secondary
All lanes:
HRP conjugated Goat anti-Rabbit (H+L) and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Predicted band size: 61 kDa
Observed band size: 55 kDa
false
Related conjugates and formulations (1)
-
Anti-CYP1B1 antibody [EPR14972] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
CYP1B1 contributes to the metabolism of various drugs and toxins helping to maintain cellular homeostasis. This enzyme also participates in the conversion of steroids and fatty acids impacting hormonal regulation and fatty acid balance. While CYP1B1 does not form a specific complex it functions within the cytochrome P450 enzyme system which collectively metabolizes numerous compounds. This functional integration within a broad enzymatic network highlights its role in chemical transformation processes.
Pathways
CYP1B1 serves an essential role in the Phase I drug metabolism pathway. This pathway includes the functionalization of xenobiotic substances to prepare them for Phase II reactions. The enzyme is involved in the hydroxylation of substrates which are important steps in both the AhR and chemical carcinogenesis pathways. CYP1B1 interacts with other cytochrome P450 family members such as CYP1A1 which further facilitates the detoxification and clearance of harmful compounds from the body.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (27)
Recent publications for all applications. Explore the full list and refine your search
Nature communications 16:7493 PubMed40796858
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cancer research communications 5:1060-1069 PubMed40478625
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cancer medicine 14:e70907 PubMed40263929
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cellular and molecular medicine 29:e70375 PubMed40016915
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 15:1438567 PubMed39188949
2024
Applications
Unspecified application
Species
Unspecified reactive species
Current protocols 4:e1003 PubMed38483112
2024
Applications
Unspecified application
Species
Unspecified reactive species
The FEBS journal 291:1780-1794 PubMed38317509
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of diabetes investigation 15:145-158 PubMed37961023
2023
Applications
Unspecified application
Species
Unspecified reactive species
Drug metabolism and disposition: the biological fate of chemicals 51:833-843 PubMed37185150
2023
Applications
Unspecified application
Species
Unspecified reactive species
Life science alliance 6: PubMed36725335
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com